Real-world safety data continue to show low incidence of major adverse cardiovascular events (MACE) among patients treated with Taltz (ixekizumab) across psoriasis, PsA, and axSpA. Registry and FAERS analyses confirm that long-term Taltz exposure does not elevate cardiovascular risk relative to comparator biologics. These findings are increasingly important given the cardiovascular burden in chronic inflammatory conditions. The stability of Taltz’s MACE profile may support its positioning in patients with comorbid cardiometabolic disease. No new safety warnings or REMS were issued in July 2025.

Citation: https://www.hcplive.com/view/ixekizumab-linked-low-risk-major-cardiovascular-events-psoriatic-patients

Implication: Cardiovascular safety could become a differentiator for Taltz in high-risk PsA and PsO populations.